ASKA Pharmaceutical Holdings Co., Ltd.
あすか製薬ホールディングス株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4886
FY2025 (Mar 2026) · J-GAAP · consolidated Source: filing S100YEAY
FY = fiscal year, named by the calendar year it starts in; the month in brackets is when it ends (FY2025 ends Mar 2026 for a March year-end). FY2025 (Mar 2026) runs Apr 1, 2025 – Mar 31, 2026.
| Gross margin | 48.0% |
|---|---|
| Operating margin | 8.2% |
| Net margin | 7.6% |
| Return on equity | 8.0%Includes one-off items (e.g. gains on negative goodwill) |
| Return on assets | 5.0% |
| Revenue growth (YoY) | 10.9% |
| EPS (basic) | ¥191.12 |
| EPS growth (YoY) | 6.2% |
| Current ratio | 2.76x |
| Equity ratio | 62.6% |
| Book value / share | ¥2,477.81 |
| Free cash flow | ¥3.4B |